TRENDING :  Market Movers  |  Top 50   FDX (-2.8%)    SPY (-1.93%)    AMZN (-3%)    VXXB (11.47%)    LVS (-2.67%)    MCD (0.24%)    NFLX (-4.47%)    NRG (-2.03%)    NXST (-3.18%)    PBR (-7.22%)    PEI (0.33%)    POST (-0.17%)    PYPL (-2.77%)    QQQ (-2.2%)    ROKU (-4.53%)    SBUX (-0.42%)    SCIF (-3.28%)    SLNO (2.35%)    WYNN (-3.5%)    XLE (-2.71%)    XLF (-2.77%)    XLU (0.73%)    XRX (-5.6%)    ZUO (-14.06%)    SQ (-4.39%)

 NVAX - Novavax

$0.54 [-0.09][-13.44%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $6.00
Low $1.75
Average $3.88
Current $0.54

CompanyAnalyst NamePT ActionActionRatingTargetDate
B. Riley FBRGeorge ZavoicoLowersMaintainsBuy$1.7503/04/19
H.C. WainwrightAnnouncesInitiates Coverage OnBuy$6.0001/28/19
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



3 Cheap Stocks to Buy That Are Worth Every Penny

InvestorPlace Stock Market News Stock Advice amp Trading Tips So close and yet so far That sums up the state of the markets recently with investors jittery over the sudden chill surrounding U S China relations In an about face on the trade dispute President Trump conceded

Why Novavax Is Soaring Today

What happened Shares of Novavax NASDAQ NVAX were soaring 14 6 higher as of 11 23 a m EDT on Wednesday after jumping as much as 25 5 higher earlier in the day There have been no new developments for the biotech since it provided an update on its fourth quarter results after

Does Novavax Have a Viable Path Forward?

Novavax NASDAQ NVAX a pre revenue vaccine developer is stuck between a rock and a hard place Following the latest clinical failure of its 160 respiratory syncytial virus RSV vaccine ResVax last month the company could be forced into making some extremely tough

What's Next for Novavax?

You might think it could be game over for Novavax NASDAQ NVAX after the clinical stage biotech reported its second late stage failure for experimental respiratory syncytial 160 virus RSV vaccine ResVax last month Unsurprisingly the biotech stock crashed hard losing

Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Novavax NASDAQ NVAX Q4 2018 Earnings Conference Call March 18 2019 4 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator Good day

Earnings Reaction History: NOVAVAX INC, 55.6% Follow-Through Indicator, 9.9% Sensitive

Expected Earnings Release 03 18 2019 PremarketExpected Earnings Release 03 18 2019 Premarket Avg Extended Hours Dollar Volume 1 298 923Avg Extended Hours Dollar Volume 1 298 923 NOVAVAX INC NVAX is due to issue its quarterly earnings report in the upcoming extended hours

Pre-Market Earnings Report for March 18, 2019 : OSTK, LL, ACRS, GPX, NVAX, FSTR, GEN, CELP, TLGT, PLX, HZN

The following companies are expected to repor t earnings prior to market open on 03 18 2019 Visit our Earnings Calendar for a full list of expected earnings releases Overstock com Inc OSTK is reporting for the quarter ending December 31 2018

Is a Beat in Store for Catabasis (CATB) This Earnings Season?

We expect Catabasis Pharmaceuticals Inc CATB to beat expectations when i t report s fourth quarter 2018 earnings on Mar 14 before market open Catabasis beat estimates in three of the past four quarters and missed the same once delivering average positive surprise of 18 11 In the

Why Novavax Stock Imploded in February

What happened Novavax NASDAQ NVAX a developmental stage vaccine company lost 69 of its value in February 160 according to data from S amp P Global Market Intelligence Novavax s shares tumbled on the last day of the month after the company reported that its

What's in the Cards for Novavax (NVAX) This Earnings Season?

Novavax Inc 160 NVAX will report fourth quarter 2018 results In the las t report ed quarter the company s loss was on par with the Zacks Consensus Estimate Moreover Novavax s earnings have met estimates in three of the trailing four quarters the average negative earnings surprise

The 3 Oldest Members of Biotech's Billion-Burned Club

Believe it or not 160 most professionals in the weird world of drug development would rather be lucky than smart That s because 99 99 of potential new drugs that look great in a petri dish eventually lose their luster before earning a nickel Every time an attempt to develop a

Can Novavax Convince the FDA Its Vaccine Deserves a Chance?

The latest clinical trial flop from Novavax NASDAQ NVAX wasn t nearly as bad as the failure it announced in 2016 but it was still a long way from what most vaccine developers would consider a success There s still a glimmer of hope though because 160 the respiratory

Why HP, Booking Holdings, and Novavax Slumped Today

Thursday was a down day on Wall Street but declines in major market benchmarks were relatively modest The Dow Jones Industrial Average finished off about 69 points while other indexes made similar percentage moves lower Market participants didn t have a particularly strong

Mid-Afternoon Market Update: Box Drops On Weak Forecast; Arcadia Biosciences Shares Gain

Toward the end of trading Thursday the Dow traded down 0 06 percent to 25 969 24 while the NASDAQ declined 0 03 percent to 7 551 96 The S amp P also fell dropping 0 04 percent to 2 791 17 Leading and Lagging Sectors Thursday afternoon the real estate shares rose 1 3

Health Care Sector Update for 02/28/2019: TGTX, NVAX, RKDA

Top Health Care StocksTop Health Care Stocks JNJ 0 9 JNJ 0 9 PFE 1 1 PFE 1 1 MRK 0 8 MRK 0 8 ABT 0 6 ABT 0 6 AMGN 0 6 AMGN 0 6 Health care stocks were mostly firmer as Thursday s regular session ended with the NYSE Health Care Index gaining 0 3 late this afternoon